定量扩散加权成像与18F-FDG-PET/CT对接受(放)化疗的头颈部鳞状细胞癌的预测价值
回顾性纳入134例经(放)化疗的头颈部鳞状细胞癌患者,其中58例治疗前同时行DWI和18F-FDG-PET/CT,31例仅行DWI,45例仅行PET/CT。校正TNM分期和HPV状态后,SUVmax-PT、ADCmax-PT、TLG-LN、ADCp20-LN可预测治疗失败,TLG-PT预测局部区域复发,MATV-PT、ADCGTV-PT、ADCSD预测死亡;联合SUVmax-PT与ADCmax-PT对治疗失败的预测优于单一参数。
要点
- 治疗前原发灶SUVmax与ADCmax联合预测治疗失败优于任一单独参数。
- TLG-LN可预测局部区域复发,ADCGTV-PT可预测死亡。
- DWI与18F-FDG-PET/CT参数对治疗失败、复发和死亡均有预测价值。
核心结论
- DWI和18F-FDG-PET/CT参数似乎对治疗失败、局部区域复发和死亡具有预测价值;联合SUVmax-PT与ADCmax-PT对治疗失败的预测优于单一参数评估。
研究设计与样本
- 回顾性纳入2012–2017年间134例组织学证实的头颈部鳞状细胞癌患者,均接受(放)化疗;58例治疗前同时行DWI和18F-FDG-PET/CT,31例仅行DWI,45例仅行PET/CT;对原发肿瘤和最大淋巴结转移灶进行定量评估,分别及联合行多因素分析。
诊断标准与关键数值
- 校正TNM分期和HPV状态后,治疗失败的预测因素为SUVmax-PT(P=0.049)、ADCmax-PT(P=0.024)、TLG-LN(P=0.031)、ADCp20-LN(P=0.047)。
- TLG-PT可预测局部区域复发(P=0.003)。
- MATV-PT(P=0.003)、ADCGTV-PT(P<0.001)、ADCSD(P=0.048)为死亡的显著预测因素。
- 同时具有两种影像的患者中,SUVmax-PT仍预测治疗失败(P=0.049),TLG-LN预测局部区域复发(P=0.003),ADCGTV-PT预测死亡(P<0.001)。
- 联合SUVmax-PT与ADCmax-PT对治疗失败的预测价值高于两者单独评估。
临床应用与阅片要点
- 治疗前可定量测量原发灶SUVmax、ADCmax及淋巴结TLG、ADCp20等参数,辅助预测治疗失败、复发和死亡风险。
- 联合原发灶SUVmax与ADCmax可能提高对治疗失败的预测能力。
局限性
- 原文为回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: In head and neck squamous cell carcinoma (HNSCC) (chemo)radiotherapy is increasingly used to preserve organ functionality. The purpose of this study was to identify predictive pretreatment DWI- and 18F-FDG-PET/CT-parameters for treatment failure (TF), locoregional recurrence (LR) and death in HNSCC patients treated by (chemo)radiotherapy.
MATERIALS AND METHODS: We retrospectively included 134 histologically proven HNSCC patients treated with (chemo)radiotherapy between 2012-2017. In 58 patients pre-treatment DWI and 18F-FDG-PET/CT were performed, in 31 patients DWI only and in 45 patients 18F-FDG-PET/CT only. Primary tumor (PT) and largest lymph node (LN) metastasis were quantitatively assessed for TF, LR and death. Multivariate analysis was performed for 18F-FDG-PET/CT and DWI separately and thereafter combined. In patients with both imaging modalities, positive and negative predictive value in TF and differences in LR and death, were assessed.
RESULTS: Mean follow-up was 25.6 months (interquartile-range; 14.0-37.1 months). Predictors of treatment failure, corrected for TNM-stage and HPV-status, were SUVmax-PT, ADCmax-PT, total lesion glycolysis (TLG-LN), ADCp20-LN (P = 0.049, P = 0.024, P = 0.031, P = 0.047, respectively). TLG-PT was predictive for LR (P = 0.003). Metabolic active tumor volume (MATV-PT) (P = 0.003), ADCGTV-PT (P < 0.001), ADCSD (P = 0.048) were significant predictors for death. In patients with both imaging modalities SUVmax-PT remained predictive for treatment failure (P = 0.049), TLG-LN for LR (P = 0.003) and ADCGTV-PT for death (P < 0.001). Higher predictive value for treatment failure was found for the combination of SUVmax-PT and ADCmax-PT, compared to either one separately.
CONCLUSION: Both DWI- and 18F-FDG-PET/CT-parameters appear to have predictive value for treatment failure, locoregional recurrence and death. Combining SUVmax-PT and ADCmax-PT resulted in better prediction of treatment failure compared to single parameter assessment.
引用
- Martens RM, Noij DP, Koopman T, et al. Predictive value of quantitative diffusion-weighted imaging and 18-F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy. Eur J Radiol. 2019. PMID: 30927958. doi:10.1016/j.ejrad.2019.01.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。